Abstract:ObjectiveA prescription cascade is a subsequent event that occurs when an adverse drug event is misinterpreted as a new medical condition, resulting in the prescription of a potentially unnecessary medication to treat this new condition. This study was designed to test the hypothesis of whether prescribing cascades exist and their magnitude among older individuals by using prescription sequence symmetry analysis (PSSA).DesignA retrospective population-based cohort study based on data from Taiwan's National Health Insurance Research Database (NHIRD), a nationwide claims-based database that covers 99% of the population in Taiwan.Setting and ParticipantsPatients receiving newly initiated index and marker drugs in the outpatient setting between 2014 and 2016 were included. Those who received index and marker drugs on the same date were excluded.MeasuresPSSA measures the propensity for a marker drug (eg, thyroxine) to be prescribed after an index drug (eg, amiodarone) has been initiated, where the index drug is suspected of inducing a side effect (eg, hypothyroidism) and the marker drug is used to treat the side effect. We evaluated 14 PSSA sets as potential prescription cascade–related drug pairs (index and marker drug), including 2 confirmatory analyses (eg, amiodarone and thyroxin), to check the validity of the PSSA results and 12 exploratory analyses of cardiovascular medication–related prescribing cascades (eg, statins and antidepressants). The observation periods for sequences of incident marker drug use were 1 year before and 1 year after the use of the incident index drug, and the symmetry of prescriptions filled for the 2 periods was examined. The results of the PSSA were performed as the crude sequence ratio (SR), defined as the ratio of patients initiating the marker drug after the index drug (causal group) to those initiating the marker drug before the index drug (noncausal group), and the adjusted SR (aSR) with 95% confidence intervals (CIs).ResultsAmong 12 potential prescription cascade–related drug pairs in exploratory analysis, 9 of them reached statistical significance, and aSR ranged from 1.02 to 1.46. Dihydropyridine calcium channel blocker–induced edema showed the highest aSR (1.46, 95% CI 1.45–1.48), and statin-induced muscle pain showed the lowest aSR (1.02, 95% CI 1.02–1.03).Conclusions and ImplicationsOur study supported the application of PSSA in detecting prescribing cascades using a nationwide claims database. Nevertheless, most previously reported prescribing cascades among cardiovascular medications were shown to have a low effect size of sequence ratios among older individuals.

Evaluating Provider and Pharmacy Discordance in Potential Calcium Channel Blocker–Loop Diuretic Prescribing Cascade

Carvedilol and Its New Analogs Suppress Arrhythmogenic Store Overload–induced Ca2+ Release

Which older adults are at highest risk of prescribing cascades? A national study of the gabapentinoid–loop diuretic cascade

Using a clinical process map to identify prescribing cascades in your patient

Identifying and quantifying potentially problematic prescribing cascades in clinical practice: A mixed‐methods study

Prescribing cascades in community‐dwelling adults: A systematic review

Potential Therapeutic Hazards Due to Drug–drug Interaction Between Topically and Systemically Coadministered Medications

Detecting Suspected Prescribing Cascades by Prescription Sequence Symmetry Analysis of Nationwide Real-World Data

Continued potassium supplementation use following loop diuretic discontinuation in older adults: An evaluation of a prescribing cascade relic

Preventing Prescribing Cascades: Ensuring Medication Safety for Older Adults

Research on prescribing cascades: a scoping review

Yonder: Prescribing cascades, teacher wait time, online services for mental health conditions, and community deep vein thrombosis pathways

Community pharmacists' awareness, identification, and management of prescribing cascades: A cross-sectional survey

Prescribing cascades of antigout medications from thiazide diuretics in gout-naïve hypertensive adults receiving first-line pharmacological management

Severe Secondary Hyperkalemia and Arrhythmia from Drug Interactions Between Calcium‐channel Blocker and Voriconazole: a Case Presentation

Developments in the epidemiology of calcium channel blocker poisoning and implications for management

Drug prescription clusters in the UK Biobank: An assessment of drug-drug interactions and patient outcomes in a large patient cohort

Dispensing pharmacy chains and direct anticoagulants: Potential associations with patient outcomes

Implementing pharmacist-prescriber collaboration to improve evidence-based anticoagulant use: a randomized trial

Drug-induced proarrhythmia: Discussion and considerations for clinical practice

Drug-drug-interactions in patients with atrial fibrillation admitted to the emergency department